Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in patients experiencing acute major bleeding while taking a Factor Xa inhibitor. The data were presented at the International Stroke Conference 2019 and published simultaneously online by The New England Journal of Medicine (NEJM).
Full data from 352 patients showed that Andexxa rapidly, and significantly, reversed anti-Factor Xa activity when administered as a bolus and sustained this reversal when followed by a 120-minute infusion.
Among all . . .